SinoCellTech (SHA: 688520) has received regulatory approval in China for finotonlimab, making it the first immuno-oncology ...

The Duchenne muscular dystrophy (DMD) market is projected to grow from $2.3 billion in 2023 to $5.2 billion in 2033 across ...

Jena-based German biotech InflaRx has announced the pricing of an underwritten public offering, raising approximately $30 ...

Robert F Kennedy Jr. has been confirmed as the new secretary of the Department of Health and Human Services (HHS) after a ...

Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

US mRNA specialist Moderna presented its fourth quarter and annual financial results on Friday, along with its 2025 guidance.

California, USA-based fibrosis specialist Pliant Therapeutics saw its shares leap 20.95% to $3.29 by close of trading ...

USA-based Agios Pharmaceuticals has announced that the ACTIVATE-Kids Phase III study of mitapivat in children aged 1 to <18 ...

A new report from industry trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) has shed a new light ...

An interview with Bayer's Bernardo Kanahuati, senior vice president, global head cardiorenal and product team lead, Kerendia, and Katja Rohwedder, senior medical affairs physician, global medical ...

Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected stage III-IV ...

Italian pharma major Recordati has reported strong preliminary consolidated financial results for 2024, with the firm’s shares edging up 2.3% to 60.40 euros.